ReviewTechnology in cancer research & treatment
Circular RNAs as Biomarkers in Breast Cancer Diagnosis, Prognosis, Molecular Types, Metastasis and Drug Resistance.
Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Subtype-Specific mInternational journal of molecular sciences · 2026Article
- The involvement of circular RNAs in breast cancer metastasis: Insight into EMT-related signaling pathways.BioImpacts : BI · 2026Review
- Polycyclic aromatic hydrocarbon derivative 3-hydroxybenz[a]anthracene promotes the progression of T47D breast cancer cells by modulating relevant protein expression.Frontiers in cell and developmental biology · 2026Article
- Therapeutic Potential of Circular RNAs as Targets for Cancer Treatment.Advanced pharmaceutical bulletin · 2025Review
- Review
- Circular RNA profiling identifies circ_0001522, circ_0001278, and circ_0001801 as predictors of unfavorable prognosis and drivers of triple-negative breast cancer hallmarks.Cell death discovery · 2025Article
- Integrated Bioinformatics and Experimental Validation of the hsa_circ_0000378/miR-205-5p/RAD51 ceRNA Axis in Breast Cancer.International journal of molecular and cellular medicine · 2025Article
- Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Circular RNAs (circRNAs), a novel class of endogenous noncoding RNA with a covalently closed continuous loop that lacks the 5'-cap structure and the 3'-poly A tail, are more stable than linear RNAs and less susceptible to degradation by nucleases. CircRNAs are widespread in multiple mammalian genomes and have been detected in various tissues, cells and body fluids. Increasing evidence shows that abnormal expression of circRNAs is involved in the development of a variety of diseases, including breast cancer. Numerous studies have explored the potential of circRNAs as biomarkers in various malignant tumors. In this review, we aim to provide a comprehensive overview of the latest advances in circRNAs as promising biomarkers in the early diagnosis, prognosis, molecular type, metastasis and drug resistance of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.